Precision BioSciences DTIL 深 沪
已收盘 08-01 16:00:00 美东时间
4.62
-0.130
-2.74%
华盛通- 最 高4.78
- 今 开4.70
- 成交量 6.19万股
- 最 低 4.53
- 昨 收 4.75
- 总市值 5122.75万
- 52周最高 11.09
- 市盈率 静 4.44
- 换手率 0.00%
- 52周最低 3.61
- 委 比 81.66%
- 总股本 1108.82万
- 历史最高 710.10
- 量 比 0.77
- 振 幅 5.26%
- 历史最低 4.02
- 每 手 1
- 风险率 1.98%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Precision BioSciences shares are trading higher after the company was granted FDA orphan drug designation for PBGENE-DMD in Duchenne muscular dystrophy.
Precision BioSciences shares are trading higher after the company was granted F...
07-23 19:05
Precision Biosciences Announced dditional Preclinical Data For PBGENE-DMD, In Vivo Gene Editing Approach For Duchenne Muscular Dystrophy (DMD), Clinical Trial Application Submission Expected In 2025 With Clinical Data Expected In 2026
New preclinical data for the PBGENE-DMD final clinical candidate demonstrates an increase in dystrophin positive muscle cells across key muscle types, potentially driven by editing of muscle satellite cells.PBGENE-DMD is
07-16 19:05
Market-Moving News for June 25th
QS: 42% | QuantumScape Achieves Key 2025 Milestone In The Scale-Up Of Its Production Capabilities With The Successful Integration Of Its Advanced Cobra Separator Process Into Baseline Cell Production DTIL: 22%
06-25 19:17
Precision BioSciences shares are trading higher after the company received FDA Rare Pediatric Disease Designation for PBGENE-DMD for the treatment of Duchenne muscular dystrophy.
Precision BioSciences shares are trading higher after the company received FDA ...
06-25 19:02
Precision BioSciences Analyst Ratings
Unity Software(U.US) reported fourth-quarter financial results after the market...
05-21 18:54
Precision BioSciences Q1 EPS $(2.21) Misses $(1.72) Estimate, Sales $29.00K Miss $5.00M Estimate
Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(2.21) per share which missed the analyst consensus estimate of $(1.72) by 28.49 percent. This is a 531.43 percent decrease over losses of $(0.35) per
05-15 19:03
Earnings Scheduled For May 15, 2025
Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is expected t...
05-15 16:32
Precision BioSciences Accelerates Development Of First-in-Class In Vivo Gene Editing Therapy PBGENE-DMD For Duchenne Muscular Dystrophy Targeting Exons 45–55 Hot Spot, IND/CTA Submission Planned For 2025 And Clinical Data Expected In 2026
- PBGENE-DMD is a first-in-class in vivo gene editing approach for the majority of Duchenne Muscular Dystrophy patients impacted by dystrophin mutations in the most common ‘hot spot' region between exons 45-55 -- Final
05-15 04:46
美股大行评级 | 潜在涨幅686.94%！Sensei Biotherapeutics获Oppenheimer升目标价至4美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1112661771769712640.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Oppenheimer：维持Sensei Biotherapeutics(SNSE)"跑赢大市"评级，目标价从3.5美元升至4美元</p> <p>• 富国银行：上调Regulus Therapeutics(RGLS)评级至
03-29 18:13
